A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer.

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and ...

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Gastric Ulcers.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.